drugset / Trial / NCT05601999

Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction

NCT05601999

Phase 3 Unknown 244 enrolled AO GENERIUM
RandomizedParallel-groupDouble-blindTreatment

Summary

GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST Elevation Myocardial Infarction (STEMI).

Timeline

Start
2021-09-03
Primary completion
2024-10
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GNR-060 Protein / enzyme biologic Intravenous
Comparator Tenecteplase Protein / enzyme biologic Intravenous